The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management.
Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.

开始日期2017-03-22

申办/合作机构

Allina Health System, Inc.

NCT01954290

/ Withdrawn临床2期IIT

Treatment of Brain Edema and Herniation Secondary to Ischemic or Hemorrhagic Stroke

Stroke remains the fourth leading cause of death in the United States (second worldwide) and a leading cause of long-term disability, resulting in total direct and indirect costs of approximately $73.7 billion annually. The failure of novel therapies in clinical trials demonstrates that the complex neural response to stroke must be targeted at multiple levels to improve patient outcomes. Despite significant improvements in stroke treatment and management, 1 year survival rate among stroke patients aged 65 years or more is around 25%, and 5- year survival rate amounts to approximately 50%. The highest chances of death are within 30 days of stroke. Mortality increases due to worsening brain dysfunction, elevated intracranial pressure (ICP), and other comorbid conditions.
Treatments aimed at reducing post-stroke cytotoxic edema may reduce the risk for development of malignant stroke and mortality. Current treatments such as osmo-therapy and hemicraniectomy have substantial limitations, and mortality remains high, despite these measures outcomes remain unsatisfactory. There is a great need for alternative medical approaches which are safe, predictable, and help to ameliorate post stroke edema.

开始日期2015-09-01

申办/合作机构

University of Florida

NCT01752543

/ Completed临床4期IIT

Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

The purpose of the present study is to evaluate the effects of a blockade of the vasopressin system and central hemodynamic system in heart failure (HF) patients during physical exercise. The significance of the vasopressin system during physical exercise is unclear. If vasopressin is a significant regulator of exercise hemodynamics in HF, strategies to intervene against activation of the V1A-receptor might be expected to improve HF symptoms and possibly outcome.
The potential effects of the central hemodynamic system will be evaluated with a Swan-Ganz catheter. Echocardiography will be performed at rest and during submaximal working capacity before and during the infusion of a vasopressin receptor antagonist (conivaptan) or placebo. Cardiac output will be measured by thermodilution. The exercise test will be performed at 50 % of VO2 max and hemodynamic and echocardiographic measurements will be collected. The exercise test will be performed on a supine multistage bicycle.

开始日期2013-12-01

申办/合作机构

Rigshospitalet

[+1]

100 项与盐酸考尼伐坦相关的临床结果

登录后查看更多信息

100 项与盐酸考尼伐坦相关的转化医学

登录后查看更多信息

100 项与盐酸考尼伐坦相关的专利（医药）

登录后查看更多信息

332

项与盐酸考尼伐坦相关的文献（医药）

2026-01-02·JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Computational approach towards repurposing of FDA approved drug molecules: strategy to combat antibiotic resistance conferred by Pseudomonas aeruginosa

Article

作者: Chatterjee, Debolina ; Sivashanmugam, Karthikeyan

Antimicrobial resistance is recognized as a major worldwide public health dilemma in the current century. Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, causes nosocomial infections like respiratory tract infections, urinary tract infections, dermatitis, and cystic fibrosis. It manifests antibiotic resistance via intrinsic, acquired, and adaptive pathways, where efflux pumps function in the extrusion of antibiotics from the cell. MexB protein, part of the tripartite efflux pumps MexAB-OprM present in P.aeruginosa, expels the penems and β-lactam antibiotics, thereby enhancing Pseudomonas resistance. The current study was intended to screen around 1602 clinically approved drugs to understand their ability to inhibit the MexB protein. Amongst them, the top 5 drug molecules were selected based on the binding energies for analyzing their physio-chemical and toxicity properties. Lomitapide was found to have the maximum negative binding energy followed by Nilotinib, whereas Nilotinib's number of hydrogen bonds was higher than that of Lomitapide. ADMET study revealed that all 5 drug molecules had limited solubility. Also, Lomitapide and Venetoclax showed low bioavailability scores, while Nilotinib, Eltrombopag, and Conivaptan demonstrated higher potential for therapeutic levels. A molecular dynamic simulation study of the 5 drugs against MexB was carried out for 200 nanoseconds. The RMSD, RMSF, Hydrogen bond formation, Radius of gyration, SASA, PCA, DCCM, DSSP and MM-PBSA binding energy calculation along with demonstrated high stability of the MexB-Nilotinib complex with lesser distortions. Our study concludes, that Nilotinib is a potential inhibitor and can be developed as a therapeutic agent against MexB protein for controlling P. aeruginosa infections.

2025-12-12·JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Identification of high-affinity inhibitors for epoxide hydrolase 2 from repurposed drugs in Parkinson’s disease therapeutics

Article

作者: Khan, Sohaib Naseem ; Shamsi, Anas ; Islam, Asimul ; Shahwan, Moyad ; Altwaijry, Nojood ; Yadav, Dharmendra Kumar ; Khan, Mohd Shahnawaz

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra that leads to bradykinesia and rest tremors. While the molecular mechanisms underlying PD are not fully understood, rising evidence shows neuroinflammation as a key factor in dopaminergic neuron damage. The soluble epoxide hydrolase (sEH) has appeared as a key player in neuroinflammation associated with PD which represents itself as a promising drug target. Here, we employed a structure-based virtual screening methodology using repurposed drugs from the DrugBank database to identify high-affinity potential inhibitors of sEH. Results showed that two hit molecules, Fluspirilene and Penfluridol, demonstrated appreciable docking potential and specificity toward the sEH active site. These molecules exhibited favorable pharmacological properties and formed critical interactions with residues essential for sEH activity. Further, all-atom molecular dynamics (MD) simulations followed by principal component analysis and free energy landscape were carried out which provide deeper insights into the conformational stability and interaction mechanisms of sEH in complex with Fluspirilene and Penfluridol. The simulation results indicated that the interaction of sEH with Fluspirilene and Penfluridol contributed to the stabilization of its structure throughout the MD trajectories of 500 ns. These findings collectively suggest that Fluspirilene and Penfluridol hold potential as repurposed leads for the development of sEH inhibitors, which offer therapeutic implications for combating PD and other associated conditions.

2025-12-01·JOURNAL OF ALZHEIMERS DISEASE

Virtual screening of drugs against multiple targets of Alzheimer's disease

Article

作者: Mesfin, Samuel ; Bloch, Naamah ; Ben Zaken, Karin ; Samson, Abraham O

Background:

Drug repurposing offers a rapid, cost-effective approach for discovering therapies against multiple targets.

Objective:

Here, we screen virtual ligand libraries consisting of 3468 approved drugs against 11 protein targets associated with Alzheimer's disease (AD).

Methods:

We employ blind molecular docking, and target amyloid-β (Aβ), microtubule-associated protein tau (MAPT), Apolipoprotein E4 (APOE4), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid-β protein precursor (AβPP), β-secretase (BACE1), brain-derived neurotrophic factor (BDNF), presenilin 1 (PSEN1) and 2 (PSEN2), and α-synuclein (SNCA) proteins using AutoDock Vina.

Results:

Notably, multitarget binding recurs among the top-10 ligands with Ergotamine and Dihydroergotamine potentially binding 8; Dutasteride 7; Drospirenone and Nilotinib 6; Adapalene and Conivaptan 5; Bromocriptine 4; and Rolapitant, Irinotecan, Plerixafor, Saquinavir, and Telmisartan 3, out of 11 protein targets. As such, we reveal potential binding sites for ergot alkaloids, steroids, retinoids, antivirals, angiotensin receptor blockers, and Neurokinin 1 (NK1) receptor antagonists on multiple AD targets. Importantly, the therapeutic potential of the top-scoring ligands is confounded by pharmacokinetics and adverse-effects. For example, poor blood-brain barrier (BBB) penetration, and vasoconstriction, discount ergot-alkaloid use in AD. Likewise, potential toxicity limits prolonged use of steroids, Nilotinib, Adapalene, and Irinotecan. Conversely, BBB penetration, neuronal protection, oral availability, anti-inflammation, and anti-hypertension, admit Angiotensin receptor blockers (ARB), (Telmisartan/Candesartan); Antidiuretic hormone (ADH) inhibitors (Conivaptan/Tolvaptan); and of the NK1 receptors antagonists (Rolapitant/Netupitant) use in AD.

Conclusions:

Our multitarget screening identifies selective synergistic AD modulators, such as ARB, ADH and NK1 receptor inhibitors, and simplifies drug discovery by focusing on the most promising candidates for experimental validation.

项与盐酸考尼伐坦相关的新闻（医药）

2026-04-23

·PRNewswire

Apotex Announces Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses

TORONTO, April 23, 2026 /PRNewswire/ - Apotex, the largest Canadian based pharmaceutical company, and Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. based specialty pharmaceutical company, today announced that they have entered into a strategic transaction to integrate Cumberland's U.S. branded businesses into Apotex (the "Transaction"). Under the terms of the agreement, Apotex will add a portfolio of branded medicines to its US business. The Transaction is expected to significantly expand Apotex's U.S. specialty and hospital focused business with a diversified basket of products across acute care, oncology, infectious disease, and gastroenterology. Closing of the Transaction is subject to, among other things, the required approval of Cumberland's shareholders. "This Transaction will strengthen our ability to support patients in some of the most critical moments of their care journey," said Jeff Watson, President & CEO of Apotex. "As a Force for Health, we are committed to improving access to high-quality medicines and ensuring that patients, families, and clinicians have the specialty treatments they rely on. Integrating Cumberland's branded commercial business into the Apotex family will enhance our ability to deliver a meaningful health impact for patients across the United States." The portfolio includes well-established brands such as Kristalose®, Caldolor®, Sancuso®, Vibativ®, Acetadote®, Vaprisol®, and Talicia®, which are prescribed across hospitals, oncology, infectious disease, and gastroenterology settings. These differentiated products benefit from strong clinical data and offer opportunities for continued commercial growth and optimization under Apotex's ownership. The portfolio of brands is an excellent strategic fit for Apotex enabling it to bolster its longstanding relationships with institutional customers and providing an opportunity to grow its position in the institutional channel. "With this Transaction, we intend to expand our U.S. commercial footprint in hospital and specialty care" said Christine Baeder, President of U.S. and LATAM. "Most importantly, we believe this Transaction will strengthen our ability to support physicians and the patients they serve. By enhancing awareness, improving access, and ensuring continuity of supply, we continue to act as a Force for Health in every community we reach." "We believe the integration of these products into Apotex creates more critical mass to better support patient care," said A.J. Kazimi, Chief Executive Officer at Cumberland. "We look forward to working with Apotex to ensure a smooth and successful transition that will expand access for patients who can benefit from our medicines." Raymond James is acting as financial advisor to Apotex in connection with the Transaction. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more at About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee. The company is focused on providing unique products that improve the quality of patient care. Cumberland currently distributes a portfolio of FDA-approved specialty brands. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information see SOURCE Apotex Inc. 21% more press release views with Request a Demo

临床2期

2026-04-16

·PRNewswire

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

A Safe and Effective Non-Opioid Pain Management Solution NASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for: Management of mild to moderate pain, including postoperative pain Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics Reduction of fever This expanded labeling reinforces Caldolor's role as a versatile, non-opioid intravenous analgesic option for use in perioperative and acute care settings. Advancing Perioperative Pain Management The newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches. Postoperative pain remains a significant challenge across surgical setting, with a growing emphasis on reducing opioid exposure while maintaining effective pain control. The updated website provides healthcare professionals with resources that focus on: The role of IV non-opioid options like Caldolor in perioperative care Strategies to support opioid stewardship amid the ongoing opioid crisis Clinical data supporting safe and effective pain and fever management with Caldolor In addition to featuring the new postoperative pain indication, the website offers comprehensive information on safety, dosing, efficacy, and access with J-Code reimbursement support. The site reinforces Caldolor as " A Safe and Effective Non-Opioid Pain Management Solution." Healthcare professionals can explore the updated website and resources at , which includes full prescribing and safety information. For medical inquiries, contact [email protected]. For product access support, contact [email protected]. About Caldolor ® (ibuprofen) Injection Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain, including postoperative pain management, as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) and patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit . About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote ® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor ® (ibuprofen) injection, for the treatment of pain and fever; Kristalose ® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso ® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol ® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia ®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website . Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

上市批准临床2期

2026-04-16

·investor.cumberlandpharma.com

CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE

A Safe and Effective Non-Opioid Pain Management Solution NASHVILLE, Tenn. , April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months and older for: Management of mild to moderate pain, including postoperative pain Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics Reduction of fever This expanded labeling reinforces Caldolor's role as a versatile, non-opioid intravenous analgesic option for use in perioperative and acute care settings. Advancing Perioperative Pain Management The newly launched Caldolor website aligns with this expanded indication, featuring dedicated content on postoperative pain management and the importance of multimodal, opioid-sparing approaches. Postoperative pain remains a significant challenge across surgical setting, with a growing emphasis on reducing opioid exposure while maintaining effective pain control. The updated website provides healthcare professionals with resources that focus on: The role of IV non-opioid options like Caldolor in perioperative care Strategies to support opioid stewardship amid the ongoing opioid crisis Clinical data supporting safe and effective pain and fever management with Caldolor In addition to featuring the new postoperative pain indication, the website offers comprehensive information on safety, dosing, efficacy, and access with J-Code reimbursement support. The site reinforces Caldolor as "A Safe and Effective Non-Opioid Pain Management Solution." Healthcare professionals can explore the updated website and resources at www.caldolor.com, which includes full prescribing and safety information. For medical inquiries, contact MSLsupport@cumberlandpharma.com. For product access support, contact orders@cumberlandpharma.com. About Caldolor® (ibuprofen) InjectionCaldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain, including postoperative pain management, as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) and patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website www.cumberlandpharma.com. Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC . There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-expanded-indication-for-caldolor-ibuprofen-injection--and-launch-of-new-brand-website-302744319.html SOURCE Cumberland Pharmaceuticals Inc. Shayla Simpson, Cumberland Pharmaceuticals Inc., (615) 255-0068; Emily Kent, Dalton Agency, (540) 621-5448

上市批准临床2期

100 项与盐酸考尼伐坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01236	盐酸考尼伐坦	C03XA02	DB00872

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心脏衰竭	美国	Cumberland Pharmaceuticals, Inc.	2005-12-29
低钠血症	美国	Cumberland Pharmaceuticals, Inc.	2005-12-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性失代偿性心力衰竭	临床3期	印度	Cumberland Pharmaceuticals, Inc.	2009-04-01
慢性低钠血症	临床2期	中国	江苏万高药业股份有限公司	2018-08-28
慢性低钠血症	临床2期	中国	北京福瑞康正医药技术研究所	2018-08-28
水中毒	临床2期	中国	北京福瑞康正医药技术研究所	2018-08-28
水中毒	临床2期	中国	江苏万高药业股份有限公司	2018-08-28
慢性心力衰竭	临床2期	美国	Cumberland Pharmaceuticals, Inc.	2002-11-01
失代偿性慢性心力衰竭	临床2期	美国	Cumberland Pharmaceuticals, Inc.	2002-11-01
肾脏疾病	临床1期	美国	Cumberland Pharmaceuticals, Inc.	2009-04-01
慢性充血性心力衰竭	临床阶段不明	美国	Astellas Pharma, Inc.	2009-07-01
类鼻疽	临床前	印度	Indian Institute of Technology Kharagpur	2025-05-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03000283 (CTgov)	临床1期	脑出血 \| 脑卒中 \| 脑水肿	7	Conivaptan	艱廠衊構窪鬱醖夢遞夢 = 蓋膚遞鑰膚選鑰遞顧獵觸膚壓憲顧壓網鏇遞範 (觸觸願齋選願積夢顧願, 製憲壓範襯憲餘艱積鬱 ~ 鏇鬱衊襯築範窪齋窪積) 更多	-	2020-04-17
NCT01451411 (CTgov)	临床3期	低钠血症	4	Conivaptan hydrochloride (Conivaptan Hydrochloride)	夢壓窪膚艱網願範簾繭(壓糧顧構鹹窪範構獵艱) = 襯廠衊膚淵廠觸觸簾獵夢憲願鹽積衊膚餘衊壓 (構餘簾網選窪蓋夢壓觸, 5.3) 更多	-	2016-03-01
				Placebo (Placebo)	夢壓窪膚艱網願範簾繭(壓糧顧構鹹窪範構獵艱) = 獵艱鹹選鏇壓積襯衊蓋夢憲願鹽積衊膚餘衊壓更多
NCT00843986 (CONVERT-H, CTgov)	临床3期	低钠血症 \| 急性失代偿性心力衰竭	9	placebo (Placebo)	選憲蓋鹹蓋繭鹹夢鏇艱(餘選夢築憲獵淵選蓋觸) = 網廠構餘繭鏇繭醖鏇夢夢糧鹽醖繭淵積鏇選衊 (範觸艱構選鏇鏇繭鑰淵, 鹹製衊築衊網網願鑰願 ~ 廠餘蓋壓蓋顧鹹構夢遞) 更多	-	2010-10-01
				conivaptan (Conivaptan)	選憲蓋鹹蓋繭鹹夢鏇艱(餘選夢築憲獵淵選蓋觸) = 襯積積願願範襯衊積獵夢糧鹽醖繭淵積鏇選衊 (範觸艱構選鏇鏇繭鑰淵, 鑰壓蓋膚衊範醖襯襯鹹 ~ 鏇繭齋選鹽廠窪醖願夢) 更多
NCT00592475 (CTgov)	临床2期	-	20	conivaptan (Regimen 1 Conivaptan 12.5 mg)	醖齋鹽積鏇齋窪積鬱選(夢簾壓醖憲網襯範簾壓) = 窪膚餘糧壓廠簾簾顧範鹹壓鹽醖蓋顧鹹衊廠鹽 (襯鏇糧築獵顧顧積遞鏇, 4.375) 更多	-	2010-09-28
				conivaptan (Regimen 2 Conivaptan 25 mg)	醖齋鹽積鏇齋窪積鬱選(夢簾壓醖憲網襯範簾壓) = 糧膚醖鹽糧廠顧夢範鑰鹹壓鹽醖蓋顧鹹衊廠鹽 (襯鏇糧築獵顧顧積遞鏇, 4.750) 更多
NCT00435591 (CTgov)	临床4期	低钠血症	121	placebo+Conivaptan (Dose Regimen 1)	壓選鏇窪願廠鑰餘築鹹 = 願餘鹽齋鹽選襯壓餘齋蓋選範構構膚顧積齋糧 (遞築壓蓋範廠鑰鏇艱製, 蓋艱壓鏇憲築衊顧繭築 ~ 範獵積繭鬱鏇觸選範醖) 更多	-	2010-05-26
				Conivaptan (Dose Regimen 2)	壓選鏇窪願廠鑰餘築鹹 = 襯願鏇夢鏇選遞鬱鏇鹹蓋選範構構膚顧積齋糧 (遞築壓蓋範廠鑰鏇艱製, 構遞夢製築獵鬱壓窪鹹 ~ 觸顧窪廠網築襯觸蓋願) 更多
NCT00478192 (CTgov)	临床3期	低钠血症	50	Conivaptan (Regimen 1 Conivaptan QD)	範衊構鬱鑰觸製廠願壓(襯構築顧築網鑰顧範構) = 鹹鹽艱衊膚鬱構築糧顧壓構壓構獵齋艱衊艱夢 (製遞顧顧網淵網齋憲顧, 4.017) 更多	-	2010-04-21
				Conivaptan (Regimen 2 Conivaptan BID)	範衊構鬱鑰觸製廠願壓(襯構築顧築網鑰顧範構) = 簾遞鑰齋構壓齋鑰製範壓構壓構獵齋艱衊艱夢 (製遞顧顧網淵網齋憲顧, 3.581) 更多